Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 57 clinical trials
Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC

therapy with a natural high-avidity TCR directed towards the HLA-A*02-restricted HBsAg peptide. This is a phase 1 clinical study of SCG101 alone and with PD-1/PD-L1 checkpoint inhibitors in HBV-related

measurable disease
  • 0 views
  • 25 May, 2022
  • 4 locations
Study of GSK3965193 in Healthy Participants and Alone and in Combination With Bepirovirsen in Participants Living With Chronic Hepatitis B Infection

GSK3965193 in healthy participants. Part 3 will evaluate the ability of GSK3965193 to lower hepatitis B virus surface antigen (HBsAg) in participants living with chronic hepatitis B infection (PLWCHB). Part

entecavir
body mass index
Accepts healthy volunteers
tenofovir
hepatitis
  • 0 views
  • 09 Jul, 2022
  • 1 location
Biomarkers Guided Stopping NAs Treatment

The primary objective of this study is to evaluate hepatitis B surface antigen (HBsAg) loss in subjects who stop nucles(t)ide analogues (NAs) (Stop arm) compared to subjects who continue

hepatitis b surface
entecavir
hepatitis b e antigen
fibroscan
hepatitis
  • 0 views
  • 25 Jan, 2021
  • 5 locations
Detecting Occult HBV Infection in Liver Donors Positive for Antibody to Hepatitis B Core Antigen (Anti-HBc) (OBI)

recipients of such grafts may not require lifelong antiviral therapy. Current markers such as HBsAg and HBV DNA are not sensitive enough to detect the presence of OBI. This is the first trial

  • 0 views
  • 08 Jun, 2022
  • 1 location
Antiviral Therapy for Patients With Chronic Hepatitis B Infection

groups. (2) Comparing the HBeAg seroconversion rates at 48 weeks and 96 weeks between the two groups. (3) The changes of HBsAg at 48 weeks and 96 weeks between the two groups. (4) Comparing adverse side

antiviral therapy
entecavir
tenofovir
hepatitis
  • 0 views
  • 08 Jun, 2022
  • 1 location
A Clinical Trial of Pembrolizumab in Patients With Hepatitis B Virus-related Hepatocellular Carcinoma, With Parallel Study on Baseline and Serial Change in the Immune Environment

environment. Subjects should have a confirmed diagnosis of HCC (in accordance with the AASLD guideline) and confirmed chronic infection with hepatitis B virus as defined by positivity for HBsAg

prothrombin
antiviral therapy
neutrophil count
measurable disease
hepatitis b surface antigen
  • 1 views
  • 13 Oct, 2022
  • 1 location
Controlled Interruption of Nucleos(t)Ide Analogue Treatment in Chronic Hepatitis B Patients (COIN-B)

In this study we will prospectively stop NA in both Caucasian and non-Caucasian patients matched for gender and age, to validate the observed host and viral parameters for future roll-out of this treatment strategy.

  • 0 views
  • 23 Oct, 2022
  • 21 locations
P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma

The main purpose of this trial is to evaluate the safety of the new adjuvant treatment of curative HCC, or the treatment of long-acting interferon P1101 alone, or the use of long-acting interferon P1101 and subsequent treatment of anti-PD1, and any efficacy in reducing the recurrence rate of patients after …

interferon
hepatitis b surface antigen
nivolumab
hepatitis
  • 1 views
  • 23 Mar, 2022
  • 1 location
Stop Hep B @ Birth

Single arm, prospective open-label study of a care model consisting of two components: Component I aims to achieve high coverage of interventions to prevent maternal-to-child transmission of hepatitis B virus: antenatal tenofovir, and timely newborn administration of hepatitis B birth dose vaccine and hepatitis B immune globulin; Component II aims …

mother-to-child transmission
encephalopathy
tenofovir
vaccination
cirrhosis
  • 0 views
  • 15 Aug, 2021
  • 1 location
Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis

Compared to TDF, peginterferon alfa 2a may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients. We design this study to compare the effectiveness and safety between the combination therapy of TDF and peg-IFN with TDF alone in …

peginterferon
fibrosis
hepatitis b antigen
liver disease
cancer
  • 3 views
  • 24 Feb, 2022
  • 1 location